GSK3β reduces risk of sporadic Parkinson's disease in ethnic Chinese

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 159 B, Issue 6, 2012, Pages 718-721

  Zhao, Dong Mei ^a   Li, Nan Nan ^a   Zhang, Jin Hong ^a,b   Chang, Xue Li ^a   Mao, Xue Ye ^a   Liao, Qiao ^a   Tan, Eng King ^c   Peng, Rong ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

GSK3 ; Parkinson's disease; SNP

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA;

ADULT; AGED; ALLELE; ARTICLE; CHINA; CHINESE; CLINICAL FEATURE; CONTROLLED STUDY; ETHNIC GROUP; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC VARIABILITY; GENOTYPE; GSK3BETA GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PROMOTER REGION; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHINA; ETHNIC GROUPS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84864955635     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.32075     Document Type: Article

References (20)

1. Belin AC, Westerlund M. 2008. Parkinson's disease: A genetic perspective. FEBS J 275: 1377-1383.
2. Das G, Misra AK, Das SK, Ray K, Ray J. 2012. Role of tau kinases (CDK5R1 and GSK3B) in Parkinson's disease: A study from India. Neurobiol Aging 30(7): 1485.e9-1485.e15.
3. Drubin DG, Kirschner MW. 1986. Tau protein function in living cells. J Cell Biol 103: 2739-2746.
4. Engel T, Lucas JJ, Gómez-Ramos P, Moran MA, Avila J, Hernández F. 2006. Cooexpression of FTDP-17 tau and GSK-3beta in transgenic mice induce tau polymerization and neurodegeneration. Neurobiol Aging 27: 1258-1268.
5. Evans W, Fung HC, Steele J, Eerola J, Tienari P, Pittman A, Silva R, Myers A, Vrieze FW, Singleton A, Hardy J. 2004. The tau H2 haplotype is almost exclusively Caucasian in origin. Neurosci Lett 369: 183-185.
6. Goris A, Williams-Gray CH, Clark GR, Foltynie T, Lewis SJG, Brown J, Ban M, Spillantini MG, Compston A, Burn DJ, Chinnery PF, Barker RA, Sawcer SJ. 2007. Tau and α-synuclein in susceptibility to, and dementia, in Parkinson's disease. Ann Neurol 62: 145-153.
7. Hanger DP, Anderton BH, Noble W. 2009. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med 15: 112-119.
8. Hughes AJ, Daniel SE, Kilford L, Lees AJ. 1992. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55: 181-184.
9. Kalinderi K, Fidani L, Katsarou Z, Clarimón J, Bostantjopoulou S, Kotsis A. 2009. GSK3β polymorphisms, MAPT H1 haplotype and Parkinson's disease in a Greek cohort. Neurobiol Aging 32: 546.e1-546.e5.
10. Kwok JB, Hallupp M, Loy CT, Chan DK, Woo J, Mellick GD, Buchanan DD, Silburn PA, Halliday GM, Schofield PR. 2005. GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Ann Neurol 58: 829-839.
11. Li Q, Michaud M, Canosa S, Kuo A, Madri JA. 2011a. GSK-3β: a signaling pathway node modulating neural stem cell and endothelial cell interactions. Angiogenesis 14: 173-185.
12. Li M, Mo Y, Luo XJ, Xiao X, Shi L, Peng YM, Qi XB, Liu XY, Yin LD, Diao HB, Su B. 2011b. Genetic association and identification of a functional SNP at GSK3β for schizophrenia susceptibility. Schizophr Res 133: 165-171.
13. Medina M, Garrido JJ, Wandosell FG. 2011. Modulation of GSK-3 as a therapeutic strategy on tau pathologies. Front Mol Neurosci 4: 24.
14. Nagao M, Hayashi H. 2009. Glycogen synthase kinase-3beta is associated with Parkinson's disease. Neurosci Lett 449: 103-107.
15. Pankratz N, Wilk JB, Latourelle JC, DeStefano AL, Halter C, Pugh EW, Doheny KF, Gusella JF, Nichols WC, Foroud T, Myers RH, PSG-PROGENI and GenePD Investigators, Coordinators and Molecular Genetic Laboratories. 2009. Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet 124: 593-605.
16. Sethi KD. 2002. Clinical aspects of Parkinson disease. Curr Opin Neurol 15: 457-460.
17. Simón-Sánchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-Ruiz C, Lichtner P, Scholz SW, Hernandez DG, Krüger R, Federoff M, Klein C, Goate A, Perlmutter J, Bonin M, Nalls MA, Illig T, Gieger C, Houlden H, Steffens M, Okun MS, Racette BA, Cookson MR, Foote KD, Fernandez HH, Traynor BJ, Schreiber S, Arepalli S, Zonozi R, Gwinn K, van der Brug M, Lopez G, Chanock SJ, Schatzkin A, Park Y, Hollenbeck A, Gao J, Huang X, Wood NW, Lorenz D, Deuschl G, Chen H, Riess O, Hardy JA, Singleton AB, Gasser T. 2009. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 41: 1308-1312.
18. Wider C, Vilarino-Guell C, Heckman MG, Jasinska-Myga B, Ortolaza-Soto AI, Diehl NN, Crook JE, Cobb SA, Bacon JA, Aasly JO, Gibson JM, Lynch T, Uitti RJ, Wszolek ZK, Farrer MJ, Ross OA. 2011. SNCA, MAPT, and GSK3B in Parkinson disease: A gene-gene interaction study. Eur J Neurol 18: 876-881.
19. Woodgett JR. 1990. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 9: 2431-2438.
20. Zhang N, Yu JT, Yang Y, Yang J, Zhang W, Tan L. 2011. Association analysis of GSK3B and MAPT polymorphisms with Alzheimer's disease in Han Chinese. Brain Res 1391: 147-153.